Ovarian Cancer Clinical Trials

21 trials recruiting in Canada.

Cancer

RecruitingDrugDeviceBehavioralOlder adultsHealthy volunteers

20 trials

Comparing 3 approaches for ovarian cancer

Explore this study →

There are 3 groups in this study. Group A receives Sacituzumab tirumotecan and Bevacizumab, together with one or more of: H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent) and Steroid mouthwash (dexamethasone or equivalent). Group B receives Sacituzumab tirumotecan, together with one or more of: Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent) and Steroid mouthwash (dexamethasone or equivalent). Group C, the comparison group, receives Bevacizumab.

Sites in Montreal, Calgary and 3 more cities

  • Phase 3
  • 3 groups
  • Sites in Calgary, Greater Sudbury and 3 more cities
  • Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Ovarian Cancer · Merck Sharp & Dohme LLC

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Ovarian Cancer trials near you.

Ovarian Cancer
Want matched now instead? →
← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.